EPH Receptor A2 antibody (Extracellular)

Catalog No. ABIN7043122

Product Details anti-EPH Receptor A2 Antibody

Target: EPH Receptor A2 (EPHA2)

Binding Specificity: AA 333-347, Extracellular

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EPH Receptor A2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (Cultured Cells) (IF (cc)), Live Cell Imaging (LCI)

Purpose: A Rabbit Polyclonal Antibody to EphA2 Receptor

Specificity: Extracellular, N-terminus.

Cross-Reactivity: Human, Mouse, Rat

Predicted Reactivity: Rat - 14,15 amino acid residues identical, mouse - 13

Characteristics: Anti-EphA2 (extracellular) Antibody (ABIN7043122, ABIN7044249 and ABIN7044250)) is a highly specific antibody directed against an epitope of human EPHA2. The antibody can be used in western blot and live cell flow cytometry applications. It has been designed to recognize EphA2 from rat, mouse, and human samples.

Purification: Affinity purified on immobilized antigen.

Immunogen:

Immunogen: Synthetic peptide

Immunogen Sequence: (C)HYLTAVGMGAKVELR, corresponding to amino acid residues 333 - 347 of human EphA2

Isotype: IgG

Application Details

Application Notes:

Antigen preadsorption control: 1 μg peptide per 1 μg antibody

Application Dilutions Immunohistochemistry paraffin embedded sections ihc: 1:300

Application Dilutions Western blot wb: 1:200

Comment:

Negative Control: BLP-ER019

Blocking Peptide: BLP-ER019

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Recosntitute with double distilled water (DDW) to a concentration of 1.0 mg/mL.

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Storage: 4 °C,-20 °C

Storage Comment:

Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.

Storage after reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

Target Details for EPH Receptor A2

Target: EPH Receptor A2 (EPHA2)

Alternative Name: EPHA2 (EPHA2 Products)

Background: Ephrin type A receptor 2, EPH Receptor A2, Epithelial Cell Kinase, Tyrosine-Protein Kinase Receptor ECK, ECK, EPHA2,Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a tyrosine kinase that belongs to the Ephrin (Eph) family of receptors. Members bind to cell surface-associated Ephrin ligands on neighboring cells. This binding generates bidirectional signaling which is a major form of contact-dependent communication between cells1. Eph receptors are divided into two classes, EphA and EphB, depending on the homology of their extracellular domains. Each extracellular domain is composed of a ligand-binding domain, Sushi domain, epidermal growth factor (EGF)-like domain, and two fibronectin type-III repeats. Eph receptors also contain a transmembrane domain, juxtamembrane region, tyrosine kinase domain, sterile alpha motif (SAM) and postsynaptic density (PSD)-95 protein, Discs large, and Zona occludens tight junction protein (PDZ) domain-binding motif.The interaction between Ephrin and the Eph receptor results in both "forward signaling" and "reverse signaling," which are mediated by Eph receptor and Ephrin, respectively2. Forward signaling induces Eph receptor oligomer clustering, cross-phosphorylation of tyrosine residues on the juxtamembrane domain and activation loop and, consequently, activation of the kinase activity.Eph receptor-ligand interactions mainly regulate cell proliferation and migration during development as well as tissue homeostasis, axon guidance, synapse plasticity, tissue remodeling, bone morphogenesis, and angiogenesis2.EphA2 is expressed in normal epidermal cells and in various solid tumors, such as breast, ovary, prostate, pancreas, glioblastoma, neck, renal, lung, melanoma, bladder and other types of cancer2.EphA2 expression in tumors is associated with a more aggressive cancer phenotype and correlates with tumor metastasis and poor patient outcome. In contrast, EphA2 also reduces cancer cell motility and proliferation and hence has both pro- and anti-oncogenic roles, depending on the cellular context3.Due to its pivotal role in various diseases, EphA2 is an appealing drug target and research is performed in order to control its activity4.

Alternative names: Ephrin type A receptor 2, EPH Receptor A2, Epithelial Cell Kinase, Tyrosine-Protein Kinase Receptor ECK, ECK, EPHA2

Gene ID: 1969

NCBI Accession: NM_004431

UniProt: P29317

Pathways: RTK Signaling